论文部分内容阅读
目的探讨p53、RAR-β2、Ki-67和EGFR在新辅助化疗前后口腔鳞癌组织细胞中的表达情况及其临床意义。方法纳入2010年4月至2014年3月收治的45例口腔鳞癌患者,采集新辅助化疗前后的口腔黏膜肿瘤组织标本,采用SP免疫组织化学方法检测p53、RAR-β2、Ki-67和EGFR的表达情况,并进行相关性比较。结果新辅助化疗前口腔鳞癌患者p53、Ki-67和EGFR的阳性表达率分别为55.56%、88.89%和77.78%,显著高于化疗后的31.11%、53.33%和55.56%(P均<0.05)。但化疗前RAR-β2阳性率(28.89%)显著低于化疗后的51.11%(P>0.05)。新辅助化疗前后口腔鳞癌组织中的Ki-67表达情况均与EGFR和p53呈正相关(P<0.05,P<0.01),但与RAR-β2不具有相关性(P>0.05)。结论新辅助化疗可能通过抑制p53基因突变、降低Ki-67和EGFR的表达,上调RAR-β2的表达,从而有效抑制肿瘤细胞的增殖。
Objective To investigate the expression of p53, RAR-β2, Ki-67 and EGFR in oral squamous cell carcinoma before and after neoadjuvant chemotherapy and their clinical significance. Methods Forty-five patients with oral squamous cell carcinoma who were treated from April 2010 to March 2014 were enrolled in this study. Oral mucosal tumor samples were collected before and after neoadjuvant chemotherapy. SP immunohistochemistry was used to detect the expression of p53, RAR-β2, Ki-67 and EGFR The expression of the situation, and correlation comparison. Results The positive rates of p53, Ki-67 and EGFR in patients with oral squamous cell carcinoma before neoadjuvant chemotherapy were 55.56%, 88.89% and 77.78%, respectively, which were significantly higher than those of 31.11%, 53.33% and 55.56% after chemotherapy ). However, the positive rate of RAR-β2 (28.89%) before chemotherapy was significantly lower than that after chemotherapy (51.11%, P> 0.05). The expression of Ki-67 in oral squamous cell carcinoma before and after neoadjuvant chemotherapy was positively correlated with EGFR and p53 (P <0.05, P <0.01), but not with RAR-β2 (P> 0.05). Conclusion Neoadjuvant chemotherapy may inhibit the proliferation of tumor cells by inhibiting the mutation of p53 gene, decreasing the expression of Ki-67 and EGFR and up-regulating the expression of RAR-β2.